GSK US news http://www.us-gsk.com/html/media-news/ GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news. GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10130.htm - Upfront and potential consideration of over $500 million Mon, 16 Nov 2009 11:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10130.htm Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine http://gsk-us.com/html/media-news/pressreleases/2009/2009_pressrelease_10129.htm GlaxoSmithKline (GSK) today announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccine. Tue, 10 Nov 2009 23:00:00 GMT http://gsk-us.com/html/media-news/pressreleases/2009/2009_pressrelease_10129.htm GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10128.htm GlaxoSmithKline (GSK) today announced that it has signed an agreement with the World Health Organization (WHO) to donate 50 million doses of its adjuvanted pandemic H1N1 influenza vaccine to WHO for distribution to developing countries most in need. Tue, 10 Nov 2009 08:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10128.htm GlaxoSmithKline and XenoPort announce extension of GSK1838262 (XP13512) FDA review date to 9 February, 2010 http://us.gsk.com/html/media-news/pressreleases/2009/2009_us_pressrelease_10081.htm GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. Mon, 09 Nov 2009 14:45:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_us_pressrelease_10081.htm Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®) http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10127.htm GlaxoSmithKline (GSK) today announced the results from the clinical trial assessing Pandemrix™, GSK’s adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal influenza vaccine, Fluarix®. Mon, 09 Nov 2009 09:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10127.htm World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine http://us.gsk.com/html/media-news/pressreleases/2009/2009_us_pressrelease_10125.htm Endorsement is first for vaccine for pneumococcal disease - a life-threatening disease affecting many children; follows first-ever World Pneumonia Day. Fri, 6 Nov 2009 10:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_us_pressrelease_10125.htm Nine area healthcare nonprofits win $40,000 each in funding from GlaxoSmithKline in partnership with the Triangle Community Foundation http://us.gsk.com/html/media-news/pressreleases/2009/2009_us_pressrelease_10079.htm Nonprofits Receive the GlaxoSmithKline 1st Annual RTP IMPACT Awards Thu, 05 Nov 2009 18:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_us_pressrelease_10079.htm World’s largest malaria vaccine trial now underway in seven African countries http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10124.htm Pivotal testing of RTS,S is on track for target enrollment of 16,000 children Tue, 03 Nov 2009 10:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10124.htm ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10123.htm Dr Dominique Limet, CEO of ViiV Healthcare, promises 'relentless pursuit' of new treatments Tue, 03 Nov 2009 08:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10123.htm Retigabine Regulatory Update http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10122.htm GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (VRX) announced today that, on 30 October, they filed a New Drug Application with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMEA), for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures Mon, 2 Nov 2009 13:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10122.htm